Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Fischer

Showing results (221-230 of 323) with videos related to

Pageof 33
Sort By:
Nucleic Acids Research|January 5, 2024
METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastomaRoshan Vaid, Ketan Thombare, Akram Mendez, et al.
Oncoimmunology|July 7, 2017
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expressionJulian P Layer, Marie T Kronmüller, Thomas Quast, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2012
A three-gene expression signature model for risk stratification of patients with neuroblastomaIdoia Garcia, Gemma Mayol, José Ríos, et al.
Critical Care (London, England)|November 25, 2011
The impact of response time reliability on CPR incidence and resuscitation success: a benchmark study from the German Resuscitation RegistryJürgen Neukamm, Jan-Thorsten Gräsner, Jens-Christian Schewe, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 30, 2022
The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastomaSilvia Lampis, Salvatore Raieli, Luca Montemurro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastomaJohannes H Schulte, Hagen S Bachmann, Bent Brockmeyer, et al.
Klinische Padiatrie|June 1, 2017
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic TumorsThorsten Simon, Barbara Hero, Johannes H Schulte, et al.
Scientific Reports|April 7, 2019
Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genesDries Rombaut, Hua-Sheng Chiu, Bieke Decaesteker, et al.
Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|August 8, 2014
German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularizationHans Krankenberg, Thilo Tübler, Sebastian Sixt, et al.
Nucleic Acids Research|April 30, 2013
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastomaMarco Lodrini, Ina Oehme, Christina Schroeder, et al.
Pageof 33

Showing results (221-230 of 323) with videos related to

Sort By:
Pageof 33
Nucleic Acids Research|January 5, 2024
METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastomaRoshan Vaid, Ketan Thombare, Akram Mendez, et al.
Oncoimmunology|July 7, 2017
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expressionJulian P Layer, Marie T Kronmüller, Thomas Quast, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2012
A three-gene expression signature model for risk stratification of patients with neuroblastomaIdoia Garcia, Gemma Mayol, José Ríos, et al.
Critical Care (London, England)|November 25, 2011
The impact of response time reliability on CPR incidence and resuscitation success: a benchmark study from the German Resuscitation RegistryJürgen Neukamm, Jan-Thorsten Gräsner, Jens-Christian Schewe, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 30, 2022
The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastomaSilvia Lampis, Salvatore Raieli, Luca Montemurro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastomaJohannes H Schulte, Hagen S Bachmann, Bent Brockmeyer, et al.
Klinische Padiatrie|June 1, 2017
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic TumorsThorsten Simon, Barbara Hero, Johannes H Schulte, et al.
Scientific Reports|April 7, 2019
Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genesDries Rombaut, Hua-Sheng Chiu, Bieke Decaesteker, et al.
Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|August 8, 2014
German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularizationHans Krankenberg, Thilo Tübler, Sebastian Sixt, et al.
Nucleic Acids Research|April 30, 2013
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastomaMarco Lodrini, Ina Oehme, Christina Schroeder, et al.
Pageof 33